Skip to main contentAI and Advanced
/
VIMTALABS · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
VI
NSE · Equity shares · Biotechnology & Drugs-20.80 · -3.38%
Vimta Labs VIMTALABS
NSE:INR 595.2
BSE:INR 595
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for VIMTALABS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 616
Day rangeINR 580 — INR 619.1
52-week rangeINR 376.05 — INR 902.85
Volume2.87 L
Market cap2,664.83
P/E21.88
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)407.69
Net Income (INR Cr)77.51
Rev Growth (5 Year %)14.11
EPS Growth (5 Year %)28.86
P/E Ratio21.88
Book Value101.18
EPS17.49
Price/BV5.88Computed
Research path: Interpret Vimta Labs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
VIMTALABSVimta Labs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 562.23 | 466.53 | 394.47 |
| Accumulated Depreciation Total | -227.05 | -186.87 | -158.76 |
| Cash Equivalents | 9.29 | Not available | Not available |
| Other Liabilities Total | 38.27 | 20.09 | 17.13 |
| Long Term Debt | 1.56 | 3.22 | 9.07 |
| Common Stock Total | 8.93 | 4.45 | 4.43 |
| Other Equity Total | -2.2 | -2.15 | -2.11 |
| Other Current Assets Total | 6.58 | 2.81 | 2.75 |
| Prepaid Expenses | 5.51 | 5.42 | 3.04 |
| Total Assets | 562.23 | 466.53 | 394.47 |
| Current Portof LT Debt/Capital Leases | 1.77 | 5.29 | 4.97 |
| Additional Paid-In Capital | 80.92 | 81.04 | 79.19 |
| Cash | 8.86 | 15.02 | 12.96 |
| Total Equity | 456.87 | 378.85 | 314.12 |
| Long Term Investments | 5 | Not available | Not available |
| Retained Earnings(Accumulated Deficit) | 369.22 | 295.51 | 232.6 |
| Total Common Shares Outstanding | 4.47 | 4.45 | 4.43 |
| Property/Plant/Equipment Total-Gross | 545.24 | 448.53 | 373.78 |
| Tangible Book Valueper Share Common Eq | 101.18 | 83.75 | 68.79 |
| Total Liabilities | 105.35 | 87.68 | 80.35 |
| Total Debt | 3.33 | 8.52 | 19.19 |
| Short Term Investments | 43.5 | 16.48 | 11.72 |
| Cashand Short Term Investments | 61.65 | 31.49 | 24.67 |
| Total Receivables Net | 118.45 | 119.53 | 99.56 |
| Notes Payable/Short Term Debt | 0 | 0 | 5.14 |
| Accounts Receivable-Trade Net | 106.79 | 106.67 | 87.18 |
| Property/Plant/Equipment Total-Net | 318.19 | 261.67 | 215.02 |
| Total Current Liabilities | 65.52 | 64.37 | 54.07 |
| Total Inventory | 32.69 | 28.56 | 27.58 |
| Accounts Payable | 11.66 | 10.49 | 8.23 |
| Other Currentliabilities Total | 52.1 | 48.58 | 35.73 |
| Total Long Term Debt | 1.56 | 3.22 | 9.07 |
| Intangibles Net | 4.93 | 6.42 | 9.09 |
| Other Long Term Assets Total | 8.94 | 8.58 | 10.6 |
| Note Receivable-Long Term | 0.3 | 2.05 | 2.18 |
| Total Current Assets | 224.87 | 187.82 | 157.6 |
| Deferred Income Tax | Not available | 0 | 0.08 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.02
Price to Sale Ratio6.54
Growth
Debt 5Yr CAGR %-35.74
Margins
Operating Margin 12m23.6
Operating Margin 5y Avg22.27
Net Profit Margin 12m19.03
Net Profit Margin 5y17.26
Yield
Dividend Yield %0.33
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk52.65
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.95 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,369.95 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,976.1 | 1.68 L | 72.73 | — |
| Cipla | INR 1,408.7 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.5 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 35.67%
- FII
- 4.41%
- MF
- 0.20%
- Other
- 59.72%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 14 August 2025Market news · 14 Aug 2025, 7:01 am
Sumeet Bagadia recommends five breakout stocks to buy today: Gujarat Apollo Industries, Vimta Labs, Skipper Ltd (India), Indian Metals and Ferro Alloys, and Shilpa Medicare.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today despite Trump's tariffs on IndiaMarket news · 1 Aug 2025, 8:00 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Alkyl Amines, IXIGO, Vimta Labs, Belrise Industries, Max India
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 30 July 2025Market news · 30 Jul 2025, 8:29 am
Sumeet Bagadia recommends five breakout stocks to buy today: Le Travenues Technology, Vimta Labs, Belrise Industries, Stallion India Fluorochemicals and Rallis India shares.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today - 21 March 2025Market news · 21 Mar 2025, 6:10 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —Welspun Corp, Kaveri Seed Company, Greenlam Industries, Vimta Labs, and Garware Technical Fibres
Breakout stocks to buy or sell: Sumeet Bagadia recommends seven shares to buy today — 19 March 2025Market news · 19 Mar 2025, 6:41 am
Sumeet Bagadia recommended buying these seven breakout shares to buy today - Aarti Pharmalabs, E I D-Parry (India), Vimta Labs, Mps, Jindal Drilling and Industries, Blue Star, and Cartrade Tech.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 17 February 2025Market news · 17 Feb 2025, 6:18 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Nitiraj Engineers, TCPL Packaging, Vimta Labs, Cartrade Tech, and Mps.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.2.0000 per share(100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsInter-alia, to consider 1. The allotment of bonus equity shares to the existing shareholders as on record date along with other items of agenda.
Rusaka Markets Community
Discussion and sentiment for Vimta Labs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Vimta Labs Limited is an India-based contract research and testing services provider. The Company operates through the Contract Research and Testing Services segment. It is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ore and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include drug discovery, development, and drug life cycle management support services; preclinical research and testing services for medical device companies; contract research and testing for agrochemical and specialty chemical companies; food testing and analytical development services to support manufacturers, processors, farmers, and retailers; contact research and development of biologics and peptides and electrical/electronic safety, environmental and physical security products testing.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- VIMTALABS
- BSE Code
- 524394
Questions
Stock FAQ
What is the symbol and ISIN of Vimta Labs?
Vimta Labs has the symbol VIMTALABS and ISIN - INE579C01029.
What is the current price of Vimta Labs?
Vimta Labs is currently trading at INR 595.20.
What are the year high and year low of Vimta Labs?
Vimta Labs has a year high of INR 902.85 and a year low of INR 376.05.
What is the market capitalization of Vimta Labs?
Vimta Labs has a market capitalization of INR 2,664.83 crore.
What is the P/E ratio of Vimta Labs?
Vimta Labs has a P/E ratio of 21.88.
What is the dividend yield of Vimta Labs?
Vimta Labs has a dividend yield of 0.33%.
How is the financial performance of Vimta Labs based on revenue, net income, and EPS?
Vimta Labs has revenue of INR 407.69 crore, net income of INR 77.51 crore, and EPS of INR 17.48.
What is the book value of Vimta Labs?
Vimta Labs has a book value of INR 101.18.
What is the debt-to-equity ratio of Vimta Labs?
Vimta Labs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Vimta Labs?
Vimta Labs has a price-to-book ratio of 5.88 and a price-to-sales ratio of 6.54.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.